Frontier Medicines
South San Francisco, US · Founded 2018 · Delaware corporation · 6 known investors
Frontier Meds develops small-molecule drugs targeting previously undruggable protein targets using a proprietary approach to identify and exploit novel binding sites across the human proteome.
Founders & leadership
JW
Jim WinklerExecutive Officer
JN
Janwillem NaesensDirector
JH
Johannes Hermann, Ph.D.Executive Officer
KW
Kevin WebsterExecutive Officer
CW
Cameron WheelerDirector
LE
Luke EvninDirector
GC
Gregory ChowExecutive Officer
CV
Chris Varma, Ph.D.Executive Officer, Director
OL
Othman LarakiDirector
Investors · 6
Reported raises · per SEC filings
Form D private placements▶$88.5MraisedJul 2021 · 17 investors · BiotechnologyRule 506(b)
▶$88.5MraisedJul 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jim WinklerExecutive Officer
- Janwillem NaesensDirector
- Johannes Hermann, Ph.D.Executive Officer
- Kevin WebsterExecutive Officer
- Cameron WheelerDirector
- Luke EvninDirector
- Gregory ChowExecutive Officer
- Chris Varma, Ph.D.Executive Officer, Director
- Othman LarakiDirector
- Offering amount
- $88.5M
- Amount sold
- $88.5M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$67MraisedNov 2020 · 31 investors · BiotechnologyRule 506(b)
▶$67MraisedNov 2020 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chris Varma, Ph.D.Executive Officer, Director
- Luke EvninDirector
- Johannes Hermann, Ph.D.Executive Officer
- Othman LarakiDirector
- Janwillem NaesensDirector
- Cameron WheelerDirector
- Jim WinklerExecutive Officer
- Kevin WebsterExecutive Officer
- Offering amount
- $67M
- Amount sold
- $67M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline | Frontier Medicinesfrontiermeds.com · 2025
- Frontier Medicines Raises $80M in Series C Funding | Precision Medicine Onlineprecisionmedicineonline.com · 2024
- Frontier Medicines Raises $80M in Series C, Targets Amgen and BMS in KRAS - BioSpacebiospace.com · 2024
- Frontier CEO weathers 'hardest financing' ever to raise $80Mfiercebiotech.com · 2024
- Frontier Medicines Raises $88.5 Million to Advance Chemoproteomics Program - BioSpacebiospace.com · 2021
- Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipelineglobenewswire.com · 2021